A Phase 2 interventional study of Bortezomib and Rituximab in Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL), sponsored by Millennium Pharmaceuticals, Inc.. Completed at 70 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Large B-Cell, Diffuse.
Among the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2009, is one of 13 in phase 2, and was the 15th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 18 · Phase 3 1
First in 1999; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 206 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 35 across the 26 interventional studies. Of the 25 that completed or were terminated, 11 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 7 studies filed under Lymphoma, Large B-Cell, Diffuse — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing bortezomib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multi-center, phase 2 study of RCHOP with or without VELCADE in adult patients with previously untreated non-(Germinal B-Cell-like) GCB Diffuse Large B-cell Lymphoma (DLBCL). The study will determine whether the addition of VELCADE to RCHOP improves progression-free survival (PFS) in patients with non-GCB DLBCL.
The drug tested in this study is called bortezomib (VELCADE®). VELCADE® was tested in people who have Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma. This study looked at the efficacy of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone] with or without VELCADE®.
The study enrolled 206 patients. Participants were enrolled in one of the two open label treatment groups:
Participants received treatment for up to six, 21-day cycles.
This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 48 months. Participants made multiple visits to the clinic, and were followed for progression free survival and overall survival until patient withdrawal, death, or 2 years after the last participant was enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
Inclusion Criteria:
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RCHOP \[rituximab, cyclophosphamide, doxorubicin, prednisone\] administered as follows: rituximab 375 mg/m\^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m\^2 IV infusion, doxorubicin 50 mg/m\^2 IV injection and vincristine 1.4 mg/m\^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Vc-RCHOP \[bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone\] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m\^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m\^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m\^2 IV infusion, doxorubicin 50 mg/m\^2 IV injection and vincristine 1.4 mg/m\^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
Drug: Bortezomib · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Bortezomib IV
Also known as: VELCADE®
Rituximab IV
Cyclophosphamide IV
Doxorubicin IV solution
Vincristine IV
Prednisone tablet
Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL)
PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.
Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Progression-Free Survival Rate
PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir. The progression-free survival rate is defined as the Kaplan-Meier (KM) estimate of progression-free survival at 2 years.
Time frame: 2 Years (Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm)
Overall Survival
Overall survival is defined as the time from the date of randomization to the date of death from any cause. A participant who is alive at the end of his/her study follow-up is censored at the date of last contact.
Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Overall Response Rate (ORR)
ORR is defined as the percentage of participants with the best overall response complete response (CR) + partial response (PR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites.
Time frame: End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]
Complete Response Rate
Complete Response Rate is defined as the percentage of participants with the best response of Complete Response (CR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease.
Time frame: End of Cycle 2, End of Treatment (Cycle 6) [Median of 16 weeks on treatment]
Duration of Response
Duration of response is defined as the time (in months) from the date of first documentation of confirmed complete response (CR) or partial response (PR) to the date of first documentation of progressive disease (PD), relapse from CR or death related to disease. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), duration of response is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using IWG-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites and PD= any new lesion or increase by \> 50% of previously involved sites from nadir.
Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Negative Rate
FDG-PET negative rate is defined as the percentage of participants FDG-PET negative at the given time-point.
Time frame: End of Cycle 2 and End of Treatment (Cycle 6) [Median of 16 weeks on treatment]
Time to Progression (TTP)
TTP is defined as the time from the date of randomization to the date of first documentation of progressive disease, relapse from CR, or death related to disease under study if participant did not have any documentation of disease progression prior to death caused by lymphoma or complications thereof. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), TTP is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.
Time frame: Median Follow-up of 34.3 months for RCHOP arm and 34.4 months for Vc-RCHOP arm
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) by Category
Percentage of participants in the following categories: • At least 1 TEAE • Drug-related, TEAEs • Grade 3 or higher TEAEs. Grade 3 are AEs of Severe Intensity • Grade 3 or higher drug-related, TEAEs • TEAEs resulting in study drug discontinuation • Serious TEAEs An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to 26 Weeks)
Percentage of Participants With Chemistry and Hematology Laboratory Values Grade 3 or Higher
Percentage of participants who shifted from a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 0, 1, or 2 at Baseline to a Grade 3 or higher on study (worst post-baseline grade). Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=Life-threatening consequences and 5=Death related to AE.
Time frame: Days 1, 4 and 10 of each cycle and end of treatment visit (Median of 16 weeks on treatment)
Participants took part in the study at 69 investigative sites in the United States from 13 October 2009 to 15 August 2015.
| Milestone | RCHOP | Vc-RCHOP |
|---|---|---|
| Started | 103 | 103 |
| Safety population: received study drug | 100 | 101 |
| Completed | 86 | 86 |
| Not completed | 17 | 17 |
| Withdrew: Adverse event | 4 | 6 |
| Withdrew: Progressive disease | 2 | 1 |
| Withdrew: Symptomatic deterioration | 1 | 0 |
| Withdrew: Withdrawal by patient | 3 | 4 |
| Withdrew: Other reason not specified | 4 | 4 |
| Withdrew: Did not receive study drug | 3 | 2 |
PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.
| months | RCHOP | Vc-RCHOP |
|---|---|---|
| Progression-Free Survival (PFS) in Patients With Non-germinal Center B-cell-like (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL) | NA (NA to NA) | NA (NA to NA) |
PFS is defined as the time in months from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause. The date of progression is the earliest date of a computed tomography/positron emission tomography (CT/PET) scan that shows evidence of PD. For a participant that has not progressed and is alive at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), PFS is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir. The progression-free survival rate is defined as the Kaplan-Meier (KM) estimate of progression-free survival at 2 years.
| percentage of participants | RCHOP | Vc-RCHOP |
|---|---|---|
| Progression-Free Survival Rate | 78 | 82 |
Overall survival is defined as the time from the date of randomization to the date of death from any cause. A participant who is alive at the end of his/her study follow-up is censored at the date of last contact.
| months | RCHOP | Vc-RCHOP |
|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) |
ORR is defined as the percentage of participants with the best overall response complete response (CR) + partial response (PR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites.
| percentage of participants | RCHOP | Vc-RCHOP |
|---|---|---|
| End of Cycle 2 | 93 (86 to 97) | 90 (82 to 95) |
| End of Treatment (Cycle 6) | 88 (80 to 94) | 84 (76 to 91) |
| Best Overall Response Rate | 98 (92 to 99) | 96 (89 to 98) |
Complete Response Rate is defined as the percentage of participants with the best response of Complete Response (CR). Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease.
| percentage of participants | RCHOP | Vc-RCHOP |
|---|---|---|
| End of Cycle 2 | 23 (16 to 33) | 16 (9 to 24) |
| End of Treatment (Cycle 6) | 45 (35 to 56) | 56 (45 to 65) |
| Best Complete Response Rate | 49 (39 to 59) | 56 (45 to 65) |
Duration of response is defined as the time (in months) from the date of first documentation of confirmed complete response (CR) or partial response (PR) to the date of first documentation of progressive disease (PD), relapse from CR or death related to disease. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), duration of response is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using IWG-revised response criteria for malignant lymphoma. CR=Disappearance of all evidence of disease and PR=Regression of measurable disease and no new sites and PD= any new lesion or increase by \> 50% of previously involved sites from nadir.
| months | RCHOP | Vc-RCHOP |
|---|---|---|
| Duration of Response | NA (NA to NA) | NA (NA to NA) |
FDG-PET negative rate is defined as the percentage of participants FDG-PET negative at the given time-point.
| percentage of participants | RCHOP | Vc-RCHOP |
|---|---|---|
| End of Cycle 2 | 42 (32 to 52) | 37 (27 to 47) |
| End of Treatment (Cycle 6) | 53 (43 to 64) | 59 (49 to 68) |
TTP is defined as the time from the date of randomization to the date of first documentation of progressive disease, relapse from CR, or death related to disease under study if participant did not have any documentation of disease progression prior to death caused by lymphoma or complications thereof. For a participant who has not progressed and is not known to have died due to disease under study at the end of his/her study follow-up or at the time of start of an alternate therapy (whichever is first), TTP is censored at the last overall response assessment that is stable disease or better, and which is prior to the start of the alternate therapy, if any. Disease response was assessed using International Working Group (IWG)-revised response criteria for malignant lymphoma. PD= any new lesion or increase by \> 50% of previously involved sites from nadir.
| months | RCHOP | Vc-RCHOP |
|---|---|---|
| Time to Progression (TTP) | NA (NA to NA) | NA (NA to NA) |
Percentage of participants in the following categories: • At least 1 TEAE • Drug-related, TEAEs • Grade 3 or higher TEAEs. Grade 3 are AEs of Severe Intensity • Grade 3 or higher drug-related, TEAEs • TEAEs resulting in study drug discontinuation • Serious TEAEs An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A Serious Adverse Event (SAE) is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| percentage of participants | RCHOP | Vc-RCHOP |
|---|---|---|
| At Least 1 TEAE | 100 | 99 |
| Drug-related, TEAEs | 88 | 95 |
| Grade 3 or higher TEAEs | 71 | 79 |
| Grade 3 or Higher Drug-related, TEAEs | 55 | 68 |
| TEAEs Resulting in Study Drug Discontinuation | 4 | 6 |
| Serious TEAEs | 31 | 34 |
Percentage of participants who shifted from a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 0, 1, or 2 at Baseline to a Grade 3 or higher on study (worst post-baseline grade). Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=Life-threatening consequences and 5=Death related to AE.
| percentage of participants | RCHOP | Vc-RCHOP |
|---|---|---|
| Lymphocytes | 70 | 86 |
| WBC Count | 68 | 69 |
| Neutrophils | 65 | 70 |
| Platelets | 18 | 39 |
| Hemoglobin | 10 | 15 |
| Hyperglycemia | 14 | 9 |
| Hypokalemia | 13 | 14 |
| Hypophosphatemia | 7 | 10 |
| Hyponatremia | 4 | 3 |
| Alanine aminotransferase (ALT) increased | 2 | 1 |
| Aspartate aminotransferase (AST) increased | 1 | 2 |
Collected over First dose of study drug through 30 days after the last dose of study drug (Up to 26 Weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RCHOP | — | 31/100 (31%) | 100/100 (100%) |
| Vc-RCHOP | — | 34/101 (33.7%) | 100/101 (99%) |
| Event | RCHOP | Vc-RCHOP |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 8/100 | 7/101 |
| DehydrationMetabolism and nutrition disorders | 2/100 | 6/101 |
| NeutropeniaBlood and lymphatic system disorders | 5/100 | 1/101 |
| PyrexiaGeneral disorders | 4/100 | 4/101 |
| SyncopeNervous system disorders | 0/100 | 4/101 |
| PneumoniaInfections and infestations | 3/100 | 1/101 |
| Herpes zosterInfections and infestations | 1/100 | 3/101 |
| Orthostatic hypotensionVascular disorders | 1/100 | 3/101 |
| PancytopeniaBlood and lymphatic system disorders | 2/100 | 1/101 |
| AnaemiaBlood and lymphatic system disorders | 2/100 | 1/101 |
| Event | RCHOP | Vc-RCHOP |
|---|---|---|
| FatigueGeneral disorders | 70/100 | 55/101 |
| NauseaGastrointestinal disorders | 56/100 | 51/101 |
| AlopeciaSkin and subcutaneous tissue disorders | 51/100 | 44/101 |
| ConstipationGastrointestinal disorders | 45/100 | 44/101 |
| NeutropeniaBlood and lymphatic system disorders | 44/100 | 38/101 |
| ThrombocytopeniaBlood and lymphatic system disorders | 20/100 | 39/101 |
| AnaemiaBlood and lymphatic system disorders | 30/100 | 37/101 |
| Neuropathy peripheralNervous system disorders | 20/100 | 32/101 |
| InsomniaPsychiatric disorders | 26/100 | 29/101 |
| Decreased appetiteMetabolism and nutrition disorders | 27/100 | 24/101 |
Intent-to-treat (ITT) Population included all randomized participants who had at least 1 dose of study drug.
| Age, Continuous(years) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| Mean | 59.8 ± 14.60 | 61.9 ± 13.81 | 60.9 ± 14.21 |
| Age, Customized(participants) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| ≤ 65 years | 58 | 55 | 113 |
| > 65 years | 42 | 46 | 88 |
| Gender(Participants) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| Female | 43 | 51 | 94 |
| Male | 57 | 50 | 107 |
| Ethnicity (NIH/OMB)(Participants) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 14 | 20 |
| Not Hispanic or Latino | 90 | 82 | 172 |
| Unknown or Not Reported | 4 | 5 | 9 |
| Race/Ethnicity, Customized(participants) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| White | 77 | 79 | 156 |
| Black or African American | 10 | 9 | 19 |
| Asian | 6 | 5 | 11 |
| Other | 4 | 5 | 9 |
| Not Reported | 3 | 3 | 6 |
| Region of Enrollment(participants) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| United States | 100 | 101 | 201 |
| Height(cm) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| Mean | 171.1 ± 11.30 | 170.3 ± 11.48 | 170.7 ± 11.37 |
| Weight(kg) | RCHOP | Vc-RCHOP | Total |
|---|---|---|---|
| Mean | 85.19 ± 20.684 | 82.86 ± 21.745 | 84.02 ± 21.203 |
1 further baseline measures are reported on the registry.
The record gives a start of Oct 2009, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bortezomib
Lymphoma, Large B-Cell, Diffuse →
Millennium Pharmaceuticals, Inc. →